10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one such opportunity window.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets.
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session – Here’s Why
Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered royalties on global sales.
Wall Street’s Most Accurate Analysts’ Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
RedHill’s Published Data Shows That Opaganib Protects Against Radiation-Induced Lung Inflammation And Fibrosis
The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing
Why Is Gilead Sciences Stock Trading Lower Today?
Gilead Sciences' global enrollment pause in magrolimab solid tumor studies. FDA issues partial clinical hold. Explore the impact on ongoing trials.
Wall Street’s Most Accurate Analysts’ Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800 million.